Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: J Bone Miner Res. 2018 Jun 22;33(10):1760–1772. doi: 10.1002/jbmr.3473

Figure 7.

Figure 7.

sActRIIB-mFc treated male oim/oim mice demonstrated upregulation of osteoblast and osteocyte marker genes as compared to vehicle treated counterparts. A) Relative fold changes of sActRIIB-mFc treated WT osteoblast (Runx2, Sp7, Dlx5, Alpl, Serpinh1, and Bglap), osteoclast (Csf1, Tnfsf11, Itgb3, and Ctsk), and osteocyte (Dmp1, Phex, Sost, and β-cat) mRNA levels with respect to vehicle treated WT mice, B) Relative fold changes of sActRIIB-mFc treated +/G610C osteoblast, osteoclast, and osteocyte mRNA levels with respect to vehicle treated +/G610C mice, and C) Relative fold changes of sActRIIB-mFc treated oim/oim osteoblast, osteoclast, and osteocyte mRNA levels with respect to vehicle treated oim/oim mice. (n=10 WT+vehicle [blue], n=10 WT+sActRIIB-mFc [blue diagonal], n=8 +/G610C+vehicle [red], n=8 +/G610C+sActRIIB-mFc [red diagonal], n=11 oim/oim+vehicle [green], and n=11 oim/oim+sActRIIB-mFc [green diagonal] [Alpl gene expression level of WT and oim/oim sample size were 7 and 8, respectively]). Values are MEAN±SD. *p<0.05; †p<0.05 vs. WT+vehicle treated mice; *bp=0.0545.